Advancements in Glioblastoma Management: A Comprehensive Review of Therapeutic Strategies and Future Directions
Main Article Content
Abstract
Glioblastoma, the most aggressive and lethal primary brain tumor, presents a formidable challenge to clinicians and researchers alike. This article provides a comprehensive overview of the latest developments in the management of glioblastoma, focusing on therapeutic strategies and emerging directions for improved patient outcomes. The aggressive nature of glioblastoma calls for a multifaceted approach, and this review examines the current state of surgical, radiotherapeutic, and chemotherapeutic interventions. Furthermore, we explore the promising avenues of targeted therapies, immunotherapy, and the role of precision medicine in tailoring treatment for individual patients. Additionally, we discuss the challenges of overcoming treatment resistance, the potential of combining modalities, and the impact of genetic and molecular profiling. This article serves as a critical resource for clinicians, researchers, and policymakers involved in the ongoing battle against glioblastoma, shedding light on the evolving landscape of glioblastoma management.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007 Aug;114(2):97- 109.
II. Central Brain Tumor Registry of the United States. CBTRUS Statistical report: Primary Brain and Central Nervous System Tumors Diagnosed in the Unites States in 2004-2007 [Internet]. CBTRUS; 2011Disponible en: http://www.cbtrus.org/2011-NPCRSEER/WEB-0407-Report-3-3-2011.pdf
III. Liu W, Zhang S, Zhang L, Cui Q, Wang J, Gui T, et al. A prognostic analysis of pediatrics central nervous system small cell tumors: evaluation of EGFR family gene amplification and overexpression. Diagn Pathol. 2014 Jul 1;9:132.
IV. Karsy M, Gelbman M, Shah P, Balumbu O, Moy F, Arslan E. Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features. Folia Neuropathol. 2012;50(4):301-21.
V. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007 May;170(5):1445-53.
VI. Ortega-Aznar A, Jimenez-Leon P, Martinez E, Romero-Vidal FJ. [Clinico-pathological and molecular aspects of diagnostic and prognostic value in gliomas]. Rev Neurol. 2013 Feb 1;56(3):161-70. [Article in Spanish]
VII. International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer Incidence And Mortality Worldwide in 2012 [Internet]. Lyon: IARC; c2015Disponible en:
http://globocan.iarc.fr/Default.aspx
VIII. Dubrow R, Darefsky AS. Demographic variation in incidence of adult glioma by subtype, United States, 1992-2007. BMC Cancer. 2011 Jul 29;11:325.
IX. Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol. 2008 Feb;10(1):10-8.
X. Moss AR. Occupational exposure and brain tumors. J Toxicol Environ Health. 1985;16(5):703-11.
XI. Navas-Acién A, Pollán M, Gustavsson P, Plato N. Occupation, exposure to chemicals and risk of gliomas and meningiomas in Sweden. Am J Ind Med. 2002 Sep;42(3):214-27.